Vertex may face another battle in the U.K. over its cystic fibrosis medicines; Astellas shows enough data for eye treatment to support expanded use, but still lags competitor

Taking stock of the drug industry, from the lab to the medicine chest

November 6, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Craig F. Walker/The Boston Globe STAT+ | Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines A U.K. agency found that Vertex's Trikafta and two other drugs sold by the company offer benefits, but are not cost-effective. By Ed Silverman STAT+ | Astellas shows enough data for eye treatment to support expanded use, but still lags competitor New data released over the weekend show the therapy still doesn't measure up to a competing treatment from Apellis Pharmaceuticals. By Adam Feuerstein STAT+ | Democrats push government to police algorithms in Medicare Advantage House Democrats are concerned the Biden administration isn't doing enough to monitor AI and algorithms used by Medicare Advantage plans. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser